Patents by Inventor Stephan D. Parent

Stephan D. Parent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12017995
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 25, 2024
    Assignee: Exelixis, Inc.
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Publication number: 20240076290
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 7, 2024
    Inventors: STEPHAN D. PARENT, TRAVIS LEE HOUSTON, COURTNEY S. JOHNSON, FANG WANG
  • Patent number: 11851424
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: December 26, 2023
    Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Stephan D. Parent, Travis Lee Houston, Courtney S. Johnson, Fang Wang
  • Publication number: 20230365618
    Abstract: Crystalline forms of thiocholesterol are disclosed herein. Such forms include crystalline Form thiocholesterol, crystalline Form B thiocholesterol, crystalline thiocholesterol Form C. Processes for making crystalline thiocholesterol, pharmaceutical compositions comprising crystalline thiocholesterol, methods of treatment comprising administering crystalline thiocholesterol, including ctystalline thiocholesterol Form A, crystalline thiocholesterol Form B, and/or crystalline thiocholesterol Form C are further provided.
    Type: Application
    Filed: October 11, 2021
    Publication date: November 16, 2023
    Inventors: ANDREW R. MIKSZTAL, WEIQI LIN, MICHAEL HOLTZ-MULHOLLAND, JULIETTE SABBATANI, TRAVIS LEE HOUSTON, STEPHAN D. PARENT
  • Publication number: 20230365619
    Abstract: Crystalline forms of crystalline sodium cholesteryl sulfate are disclosed herein. Such forms include crystalline sodium cholesteryl sulfate Form B, crystalline sodium cholesteryl sulfate Form F, crystalline sodium cholesteryl sulfate Form H, crystalline sodium cholesteryl sulfate Form J, crystalline sodium cholesteryl sulfate Form K, crystalline sodium cholesteryl sulfate Form L, crystalline sodium cholesteryl sulfate Form M, and crystalline sodium cholesteryl sulfate Form N. Processes for making such crystalline forms and methods of treating disease with form are further provided.
    Type: Application
    Filed: October 11, 2021
    Publication date: November 16, 2023
    Inventors: WEIQI LIN, STEPHAN D. PARENT, COURTNEY S. JOHNSON
  • Publication number: 20230312602
    Abstract: Disclosed herein are salt and solvate forms of. (1S,3?R,6?R,7?S,8?E,11?S,12?R)-6-chloro-7?-methoxy-11?,12?-dimethyl-3,4-dihydro-2H,15?H-spiro[naphthalene-1,22?-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15?-one 13?,13?-dioxide (AMG 176): such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.
    Type: Application
    Filed: April 5, 2023
    Publication date: October 5, 2023
    Inventors: Henry Morrison, Jason S. Tedrow, Stephan D. Parent, Courtney Johnson, Travis Houston, Melanie Bevill
  • Publication number: 20230279021
    Abstract: Crystalline forms of a GABAA ?5 agonist, pharmaceutical compositions and combinations comprising those crystalline forms, their use in methods of treating cognitive impairment associated with central nervous system (CNS) disorders, cognitive impairment associated with brain cancer, the brain cancer itself or Parkinson's disease psychosis and methods of producing the crystalline forms.
    Type: Application
    Filed: July 9, 2021
    Publication date: September 7, 2023
    Inventors: Deepa Gandla, Brian Gregg, Vishnumurthy Hegde, Stephan D. Parent, Travis Lee Houston
  • Publication number: 20230174541
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: September 2, 2022
    Publication date: June 8, 2023
    Inventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
  • Publication number: 20230128815
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides salt forms, formulations, and pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds, salt forms, or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: March 23, 2021
    Publication date: April 27, 2023
    Inventors: J Tyler MARTIN, Jared William WENGER, Stephan D PARENT, Courtney S JOHNSON, Eric Jon FARRIS, Gui LIU
  • Publication number: 20230056273
    Abstract: Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein.
    Type: Application
    Filed: December 23, 2020
    Publication date: February 23, 2023
    Inventors: ANDREW R. MIKSZTAL, SHAWN JOHNSTONE, MICHAEL HOLTZ-MULHOLLAND, FLAVIO LOPEZ, HOWARD SARD, JIE LI, MARIO GONZALEZ, STEPHAN D. PARENT, TRAVIS LEE HOUSTON, ROBERT WENSLOW
  • Publication number: 20230052703
    Abstract: The present invention relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid crystalline salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: December 12, 2019
    Publication date: February 16, 2023
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Publication number: 20230029213
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: December 12, 2019
    Publication date: January 26, 2023
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Publication number: 20220395492
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Application
    Filed: August 10, 2022
    Publication date: December 15, 2022
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Publication number: 20220371994
    Abstract: A crystalline polymorphic form of psilocin is disclosed. The beneficial and therapeutic uses of the crystalline form and of compositions containing the crystalline form are also disclosed. The disclosure sets out methods of making and characterizing the crystalline form.
    Type: Application
    Filed: May 5, 2022
    Publication date: November 24, 2022
    Inventors: Nate Schultheiss, Travis Lee Houston, Stephan D. Parent
  • Publication number: 20220363674
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 17, 2022
    Inventors: Stephan D. Parent, Travis Lee Houston, Courtney S. Johnson, Fang Wang
  • Patent number: 11479557
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: October 25, 2022
    Assignee: VITAE PHARMACEUTICALS, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Patent number: 11452720
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: September 27, 2022
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Publication number: 20220289675
    Abstract: An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.
    Type: Application
    Filed: August 19, 2020
    Publication date: September 15, 2022
    Applicant: ONO PHARMACEUTICALCO.,LTD.
    Inventors: Shuhei OTANI, Takayuki FUJITO, Naoko IMURA, Hideomi KIJIMA, Stephan D. PARENT, Melanie Janelle BEVILL, Courtney S. JOHNSON, Travis Lee HOUSTON
  • Publication number: 20220235045
    Abstract: The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1- piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 28, 2022
    Inventors: Mary CHAVES, Ron C. KELLY, Prashant AGARWAL, Stephan D. PARENT, Darren Leonard REID, Roman SHIMANOVICH
  • Patent number: 11173156
    Abstract: Forms of 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I and salts or co-crystals thereof.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 16, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Vinod Khetarpal, Travis Lee Houston, Stephan D. Parent, Jian-xie Chen, Charles H. Montgomery, Geetha Banda